Skip to main content

Table 5 GRADE assessments for the body of evidence for each outcome and judgment of the overall quality of evidence

From: Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review

Outcome Follow-up Risk of bias Inconsistency Indirectness Imprecision Publication bias Overall quality of evidence
Primary outcomes
Change in CT score        
Lund-McKay Score 16 weeks Moderate limitation Not relevant No serious indirectness Serious imprecision Unlikely Low
Percent opacification on CT 6 months Moderate limitation Not relevant No serious indirectness Serious imprecision Unlikely Low
Change in clinical polyp score        
Total nasal endoscopic polyp score 16 weeks; 6 months Moderate limitation Not relevant No serious indirectness Serious imprecision Unlikely Low
Change in quality of life        
SF-36 16 weeks Moderate limitation Not relevant No serious indirectness Serious imprecision Unlikely Low
AQLQ 16 weeks Moderate limitation Not relevant No serious indirectness Serious imprecision Unlikely Low
RSOM-31 16 weeks Moderate limitation Not relevant No serious indirectness Serious imprecision Unlikely Low
TNSS 6 months Moderate limitation Not relevant No serious indirectness Serious imprecision Unlikely Low
SNOT-20 6 months Moderate limitation Not relevant No serious indirectness Serious imprecision Unlikely Low
Secondary outcomes
Change in cellular inflammation        
Eosinophil count (nasal lavage) 6 months Moderate limitation Not relevant No serious indirectness Serious imprecision Unlikely Low
Change in nasal airflow        
PNIF 6 months Moderate limitation Not relevant No serious indirectness Serious imprecision Unlikely Low
Change in olfaction        
UPSIT 6 months Moderate limitation Not relevant No serious indirectness Serious imprecision Unlikely Low
Adverse events 16 weeks; 6 months Moderate limitation Not relevant No serious indirectness Serious imprecision Unlikely Low
  1. SF-36 36-Item Short Form Health Survey, AQLQ Asthma Quality of Life Questionnaire, RSOM-31 Rhinosinusitis Outcome Measure 31, TNSS Total Nasal Symptom Severity, SNOT-20 Sinonasal Outcome Test 20, PNIF peak nasal inspiratory flow, UPSIT University of Pennsylvania Smell Identification Test